Systems and methods for combined cosmetic treatment of cellulite with ultrasound
Dermatological cosmetic combination treatments with high intensity focused ultrasound, dermal fillers, fat-reducing compounds, cavitation-prone fluids, and/or septa dissection are provided. A HIFU therapy system can include an imaging system, methods adapted to alter placement and position of a line focus band therapy, multiple simultaneous cosmetic ultrasound treatment zones in tissue, and dithering ultrasound beams from a transducer to alter placement and position of multiple cosmetic treatment zones in tissue. The HIFU systems can include a hand wand, removable transducer modules, and a control module. The dermal fillers can include hydroxyapatite. The fat-reducing compounds can include adipocytolytic compounds, pentacyclic triterpenoid compounds, proapoptotic compounds, compounds impairing differentiation of pre-adipocytes, and combinations thereof. The cavitation-prone fluids can include molecules dissolved in fluids, ethanol, glycerin, and ethylene glycol. The septa dissecting can include using a cutting blade and/or cavitation HIFU. The cosmetic treatment system may be used in various cosmetic procedures, such as treating cellulite.
1. A method of treating gynoid lipodystrophy, the method comprising:
applying high intensity focused ultrasound (HIFU) therapy to a tissue region below a skin surface;
injecting a first compound into the tissue region treated by the HIFU;
wherein the first compound comprises a dermal filler,
wherein the dermal filler comprises calcium hydroxyapatite, and
injecting a second compound into the tissue region treated by the HIFU;
wherein the second compound comprises a fat-reducing compound,
wherein the fat-reducing compound comprises polidocanol,
administering a second treatment 90±10 days later, comprising:
focusing the second HIFU at a depth 1.5 mm below the skin surface,
wherein the second HIFU therapy is applied at 10 MHz,
wherein the second calcium hydroxyapatite is injected in a dermis layer below the skin surface,
wherein the second calcium hydroxyapatite is provided in a final concentration of 25-31% w/w,
wherein the second polidocanol is injected in a subcutaneous fat below the skin surface, and
wherein the second polidocanol is provided in a final concentration of 0.5% w/v;
thereby treating gynoid lipodystrophy.
2. The method of claim 1 , further comprising reapplying HIFU after the dermal filler is injected to harden the dermal filler.
3. The method of claim 1 , further comprising
focusing the HIFU at a depth 1.5 mm below the skin surface,
wherein the HIFU therapy is applied at 10 MHz,
wherein the calcium hydroxyapatite is provided in a final concentration of 25-31% w/w,
wherein the polidocanol is provided in a final concentration of 0.5% w/v.
4. The method of claim 1 ,
wherein the second calcium hydroxyapatite is provided in a final concentration of 25% w/w.
5. The method of claim 1 , wherein the calcium hydroxyapatite is provided in a final concentration of 25-31% w/w and wherein the polidocanol is provided in a final concentration of 0.5% w/v.
6. The method of claim 1 , further comprising reapplying HIFU after the dermal filler is injected, thereby modifying a viscosity of the dermal filler by the application of HIFU, and shaping the dermal filler into a designed structure by the application of HIFU.
7. The method of claim 1 , further comprising dissecting at least one septa in the dermis layer with a septae dissection technology.
8. The method of claim 1 , further comprising
administering the dermal filler by local injection into a dermal tissue, a subcutaneous fat tissue, or both the dermal tissue and the subcutaneous fat tissue.
9. The method of claim 1 , further comprising
focusing the HIFU at fat tissue, wherein two or more simultaneous focused ultrasound treatments heat up portions of the fat tissue.
10. A method for cosmetically treating gynoid lipodystrophy comprising:
administering to a subject in need thereof an effective amount of HIFU energy and at least one of a dermal filler and a fat-reducing compound,
administering a second treatment 90±10 days later a second HIFU energy and a dermal filler comprising calcium hydroxyapatite and a fat-reducing compound comprising polidocanol, comprising:
focusing the second HIFU energy at a depth 1.5 mm below a skin surface,
wherein the second HIFU therapy is applied at 10 MHz,
wherein the calcium hydroxyapatite is injected in a dermis layer below the skin surface,
wherein the calcium hydroxyapatite is provided in a final concentration of 25-31% w/w,
wherein the polidocanol is injected in a subcutaneous fat below the skin surface, and
wherein the polidocanol is provided in a final concentration of 0.5% w/v.
11. The method for cosmetically treating gynoid lipodystrophy of claim 10 , wherein the HIFU is administered concurrently, sequentially or separately with at least one of the group consisting of: a dermal filler and a fat-reducing compound.
12. The method for cosmetically treating gynoid lipodystrophy of claim 10 , wherein the dermal filler comprises calcium (hydroxy)phosphate particles.
13. The method for cosmetically treating gynoid lipodystrophy of claim 10 , wherein the fat-reducing compound and the calcium hydroxyapatite are administered concurrently, sequentially or separately.
14. A method for producing an aesthetic ultrasound effect, comprising:
applying ultrasound to a tissue region below a skin surface;
injecting a first compound into the tissue region treated by the ultrasound;
wherein the first compound comprises a dermal filler,
wherein the dermal filler comprises calcium hydroxyapatite, and
injecting a second compound into the tissue region treated by the ultrasound;
wherein the second compound comprises a fat-reducing compound,
wherein the fat-reducing compound comprises polidocanol
administering a second treatment 90±10 days later, comprising:
focusing the second ultrasound at a depth 1.5 mm below the skin surface,
wherein the second ultrasound is applied at 10 MHz,
wherein the second calcium hydroxyapatite is injected in a dermis layer below the skin surface,
wherein the second calcium hydroxyapatite is provided in a final concentration of 25-31% w/w,
wherein the second polidocanol is injected in a subcutaneous fat below the skin surface, and
wherein the second polidocanol is provided in a final concentration of 0.5% w/v.
15. The method of claim of 14 , further comprising applying a cavitation-prone agent to the tissue region treated by the ultrasound.
16. The method of claim of 14 , further comprising applying an additional energy source to the tissue region treated by the ultrasound.
17. The method of claim 16 , wherein the additional energy source comprises one or more of the group consisting of: visible light, laser, radio-frequency, microwave, electromagnetic, cryogenic, electron beam, and magnetic energy.
18. The method of claim 14 , wherein said ultrasound comprises high intensity focused ultrasound (HIFU).
19. The method of claim 14 , wherein the dermal filler comprises calcium (hydroxy)phosphate particles selected from the group consisting of: monocalcium phosphate (MCP), dicalcium phosphate (DCP), calcium dihydrogen phosphate (CDP), tricalcium phosphate (TCZ) including its α-, α′- and β-polymorphs, octacalcium phosphate (OCP), biphasic tricalcium phosphate (BCP), and hydroxyapatite.
20. The method of claim 14 , wherein the aesthetic ultrasound effect comprises at least one of the group consisting of: a cellulite treatment, reducing wrinkles, sagging and/or laxity of the skin, reducing fat, body sculpting, and facial sculpting.